Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine...
October 30 2020 - 2:30AM
Novo Nordisk's operating profit increased by 6% in Danish kroner
and by 7% at constant exchange rates (CER) in the first nine months
of 2020
30 October 2020 - Financial report for the period 1
January 2020 to 30 September 2020
- Sales increased by 6% in Danish kroner and by 7% at CER to DKK
94.8 billion. Sales in International Operations increased by 9% in
Danish kroner (12% at CER), and sales in North America Operations
increased by 2% in Danish kroner (2% at CER). Sales growth was
negatively impacted by COVID-19 as fewer patients initiated
treatment, partially offset by COVID-19-related stocking in the
first quarter.
- Sales within Diabetes and Obesity care increased by 6% to DKK
80.3 billion (8% at CER), driven by GLP-1 sales increasing by 29%
in Danish kroner (29% at CER) reflecting the uptake of Ozempic® and
the Rybelsus® launch as well as Obesity care sales increasing by 3%
in Danish kroner (6% at CER). Biopharm sales increased by 3% (4% at
CER).
- Sales in the third quarter increased by 2% measured in Danish
kroner and by 7% at CER compared to the third quarter of 2019.
Sales growth was driven by GLP-1 sales increasing by 25% in Danish
Kroner (31% at CER).
- During the third quarter, Novo Nordisk successfully completed
the phase 2b trial with ziltivekimab in cardiovascular disease.
Further, Novo Nordisk requested priority review in the US of the
filing of semaglutide 2.4 mg in obesity based on a priority review
voucher.
- On 8 October, the outlook for 2020 was raised with sales growth
and operating profit growth now both expected to be 5-8% at
CER.
PROFIT AND
LOSS |
9M 2020 |
9M 2019 |
Growth as reported |
Growth at CER* |
DKK
million |
|
|
|
|
Net sales |
94,808 |
89,604 |
6% |
7% |
Operating profit |
42,948 |
40,610 |
6% |
7% |
|
|
|
|
|
Net
profit |
32,820 |
30,234 |
9% |
N/A |
Diluted
earnings per share (in DKK) |
14.00 |
12.68 |
10% |
N/A |
* CER: Constant exchange rates (average 2019). The growth at CER
was announced on 8 October
Lars Fruergaard Jørgensen, president and CEO:
"We are very satisfied with the performance in the first nine
months of 2020 despite the negative impacts from COVID-19. More
patients use our GLP-1 treatments, and our diabetes market
leadership continues to expand. Within R&D, an important
milestone was reached with the encouraging results from the phase
2b trial in cardiovascular disease with ziltivekimab, the lead
candidate from Corvidia Therapeutics that was acquired this
year".
On 30 October 2020 at 13.00 CET, corresponding to 8.00 am EDT, a
conference call will be held. Investors will be able to listen in
via a link on novonordisk.com, which can be found under
‘Investors’.
About Novo NordiskNovo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat diabetes and
other serious chronic diseases such as obesity and rare blood and
endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to
prevent and ultimately cure disease. Novo Nordisk employs about
44,000 people in 80 countries and markets its products in around
170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com,
Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Ken Inchausti
(US) |
+1 609 240
9429 |
kiau@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079 0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
Mark Joseph
Root |
+45 3079 4211 |
mjhr@novonordisk.com |
Kristoffer Due
Berg (US) |
+1 609 235
2989 |
krdb@novonordisk.com |
Company announcement No 63 / 2020
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Oct 2023 to Oct 2024